Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources
Gastrointestinal and Other Cancers Research Group

Publications

View All  |  2014-2010  |  2009-2000

  • Coming soon.
  • Coming soon
  • Falk GW, Buttar NS, Foster NR, Ziegler KL, Demars CJ, Romero Y, Marcon NE, Schnell T, Corley DA, Sharma P, Cruz-Correa MR, Hur C, Fleischer DE, Chak A, Devault KR, Weinberg DS, Della'zanna G, Richmond E, Smyrk TC, Mandrekar SJ, Limburg PJ; Cancer Prevention Network. A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's Esophagus. Gastroenterology. 2012 Jul 11. [Epub ahead of print]
    [ PubMed Abstract ]
  • Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M,Carpenter PM, McLaren C, Meyskens FL Jr, Brenner DE. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res. 2011 Mar; 4(3): 354-64.
    [ PubMed Abstract ]
  • Limburg PJ, Mahoney MR, Ziegler KL, Sontag SJ, Schoen RE, Benya R, Lawson MJ, Weinberg DS, Stoffel E, Chiorean M, Heigh R, Levine J, Della'Zanna G, Rodriguez L, Richmond E, Gostout C, Mandrekar SJ, Smyrk TC; for the Cancer Prevention Network. Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention. Cancer Prev Res. 2011 Feb;4(2):259-269.
    [ PubMed Abstract ]
  • Lipkin S, Lee J, Imagawa D, Hewitt Sm, Chris Tucker, Zell J, Wong V, Garcia A, Gonzalez R, Della Zanna G, Richmond E, Rodriguez LM, and Meyskens F. Phase IIa trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms. Letter. Cancer Prev Res. Spring 2011 (in press).
  • Bailey HH, Kim K, Verma AK, Sielaff K, Larson PO, Snow S, Lenaghan T, Viner JL, Douglas J, Dreckschmidt NE, Hamielec M, Pomplun M, Sharata HH, Puchalsky D, Berg ER, Havighurst TC, Carbone PP. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res. 2010 Jan;3(1):35-47.
    [ PubMed Abstract ]
  • Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG; Adenoma Prevention with Celecoxib (APC) Study Investigators. Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer Prev Res. 2010 May;3(5):588-96.
    [ PubMed Abstract ]
  • Caulin AF, Maley CC. Peto's Paradox: evolution's prescription for cancer prevention. Trends Ecol Evol. 2011 Feb 4.
    [ PubMed Abstract ]
  • Dunn BK, Richmond ES, Minasian LM, Ryan AM, Ford LG. A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). Nutr Cancer. 2010 Oct;62(7):896-918. Review.
    [ PubMed Abstract ]
  • Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, Kang S, Linden KG, Heffernan M, Duvic M, Richmond E, Elewski BE, Umar A, Bell W, Gordon GB. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2010 Dec 15;102(24):1835-44.
    [ PubMed Abstract ]
  • Lynch PM, Ayers GD, Hawk E, Richmond E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Half E, Burke CA. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol. 2010 Jun;105(6):1437-43.
    [ PubMed Abstract ]
  • Merlo LM, Maley CC. The role of genetic diversity in cancer. J Clin Invest. 2010 Feb 1;120(2):401-3.
    [ PubMed Abstract ]
  • Merlo LM, Shah NA, Li X, Blount PL, Vaughan TL, Reid BJ, Maley CCA comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res. 2010 Nov;3(11):1388-97. Epub 2010 Oct 12.
    [ PubMed Abstract ]
  • Pinsky PF, Fleshman J, Mutch M, Rall C, Charabaty A, Seligson D, Dry S, Umar A, Schoen RE. One year recurrence of aberrant crypt foci. Cancer Prev Res (Phila). 2010 Jul;3(7):839-43.
    [ PubMed Abstract ]
  • Richmond E, O'Mara A. Conducting chemoprevention clinical trials: challenges and solutions. Semin Oncol. 2010 Aug;37(4):402-6. Review.
    [ PubMed Abstract ]
  • Thompson PA, Wertheim BC, Zell JA, Chen WP, McLaren CE, LaFleur BJ, Meyskens FL, Gerner EW. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Gastroenterology.  2010 Sep;139(3):797-805, 805.e1.
    [ PubMed Abstract ]
  • Umar A, Della'Zanna G, Lubet R. Further thoughts on preclinical animal models for cancer prevention: when is it best to start treatment? What are potential histopathologic endpoints? Semin Oncol. 2010 Aug;37(4):339-44. Review.
    [ PubMed Abstract ]